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Abstract
Background: Multiple endocrine neoplasia type 2 is an autosomal dominant disorder. MEN 2A is
characterized by medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism;
MEN 2B by medullary thyroid carcinoma, pheochromocytoma and characteristic stigmata.
Activating germline mutations of the RET proto oncogene are responsible for this hereditary
syndrome. Codon 634 mutations are the most common mutations occurring in MEN 2A families
whereas a specific mutation at codon 918 is observed in the great majority of MEN 2B families.
Analysis of these codons will provide a final diagnosis in the great majority of affected families
making unnecessary further studies. To specifically study the codons 634 and 918 we used a
minisequencing method as an alternative method to complete sequencing.
Results: Using this mutation detection method we were able to reproduce in all cases,
representative of 7 families, the information previously obtained by direct sequencing of PCR
products. Depending on the number of primers used in the minisequencing reaction, we were able
to interrogate either only one nucleotide of the target codon or the three nucleotides
simultaneously.
Conclusions: This technique appears as a simple, rapid and efficient method for genetic screening
of MEN 2 families. It can be utilized to seek for unknown mutations at specific codons or to screen
for previously identified mutations and is therefore of interest to study index cases or individuals
at risk. Results suggest that complete sequencing is unnecessary.
Background
The multiple endocrine neoplasia (MEN) type 2 syn-
dromes comprise three related autosomal dominant can-
cer syndromes [1]. MEN 2A is characterised by medullary
thyroid carcinoma (MTC), pheochromocytoma and par-
athyroid hyperplasia or adenoma [2]. MEN 2B is similar
to MEN 2A except that hyperparathyroidism is rare and
characteristic abnormalities such as marfanoid habitus,
mucocutaneous and intestinal tract ganglioneuromatosis
are present [3]. In familial medullary thyroid carcinoma
(FMTC), medullary thyroid carcinoma is the only mani-
festation [4].
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encodes for a receptor tyrosine kinase, are the underlying
cause of MEN 2 [5–7].
The majority of mutations in MEN 2A and FMTC families
are found in 1 of 5 cysteine codons (609, 611, 618 and
620 in exon 10 and 634 in exon 11) that encode part of
the extracellular cysteine rich domain [1,8,9]. Codon 634
mutations are the most common in MEN 2A families oc-
curring in 85% of these families [1]. Mutations in FMTC
families are evenly distributed among the 5 cysteine co-
dons [1,8]. Less frequently, mutations are found else-
where in the RET[10–13]. The great majority of MEN 2B
families (95%) present the same mutation (ATG→ ACG)
at codon 918 in exon 16 [1]. In a few cases of MEN 2B
families a mutation was found in exon 883 [14]. Analysis
of codons 634 and 918 of the RET proto oncogene will
therefore provide a final diagnosis in the great majority of
2A and 2B families.
Different methods have been used to identify RET proto
oncogene mutations from which sequencing is the gold
standard. In the present study, we adapted the primer ex-
tension technique [15], more frequently known as the
minisequencing method [16,17], to mutational analysis
of MEN 2 families. The detection of the products obtained
was performed on a capillary electrophoresis system.
Results and Discussion
Mutations at codon 634 were identified either by a single
reaction or a multiplex reaction. Using only one primer to
interrogate the first nucleotide, patients harbouring the
TGC→CGC mutation presented two peaks corresponding
to T/C reactions as shown in figure 1 in contrast with a sin-
gle peak observed in normal individuals (fig 2). When the
three nucleotides were analysed simultaneously, by a
multiplex reaction, patients presented an additional
fourth peak corresponding to the mutation (fig 3). Simi-
larly, using only one primer to interrogate the second nu-
cleotide, patients harbouring the TGC→TAC mutation
presented two peaks corresponding to G/A reactions (fig
4) in contrast with a single peak observed in normal indi-
viduals (fig 5). Simultaneous analysis of the three nucle-
otides reproduced results documenting a fourth peak
corresponding to the mutation (fig 6).
Study of the 2B patient was performed with a single prim-
er designed to screen the most common mutation within
exon 16, at codon 918, ATG→ACG. The patient was het-
erozygous for the mutation showing two differently col-
oured peaks corresponding to T/C reactions (fig 7) in
contrast with a single peak corresponding to T reaction
observed in a normal individual (fig 8).
Using the minisequencing method we were able to recog-
nize all mutations tested (C634R, C634Y, M918T).
Present data support the usefulness of a multiplex reac-
tion to identify the mutation responsible for the disease in
a particular family whereas subsequent screening of indi-
viduals at risk is possible performing a single reaction.
Conclusions
Germline mutations occurring in MEN 2 families are clus-
tered in a few codons of RET proto oncogene. Whereas the
great majority of MEN 2A families present different muta-
Figure 1
Analysis of the first nucleotide of codon 634 by a single reac-
tion – pattern observed in an individual heterozygous for the
mutation T/C at the first position. Colour is assigned to indi-
vidual ddNTPs as follows: green/A, black/C, blue/G, red/T.
Figure 2
Analysis of the first nucleotide of codon 634 by a single reac-
tion – normal pattern corresponding to the homozygous
wild type. Colour is assigned to individual ddNTPs as follows:
green/A, black/C, blue/G, red/T.Page 2 of 5
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present a single mutation at codon 918.
Among different PCR based methods used to identify RET
proto oncogene mutations in MEN 2 families, complete
sequencing is the most reliable procedure.
To specifically study codons 634 and 918 we used a min-
isequencing method as an alternative method to complete
sequencing.
Using this mutation detection method we were able to re-
produce in all cases the information previously obtained
by direct sequencing of PCR products.
Major advantages of the minisequencing method include
its lower cost and speed.
The same procedure may be useful for diagnosis of other
genetic disorders associated with point mutations at spe-
cific codons.
Figure 3
Analysis of the three nucleotides of codon 634 by a multiplex
reaction – pattern observed in an individual heterozygous for
the mutation T/C at the first position. Colour is assigned to
individual ddNTPs as follows: green/A, black/C, blue/G, red/
T.
Figure 4
Analysis of the second nucleotide of codon 634 by a single
reaction – pattern observed in an individual heterozygous for
the mutation G/A at the second position. Colour is assigned
to individual ddNTPs as follows: green/A, black/C, blue/G,
red/T.
Figure 5
Analysis of the second nucleotide of codon 634 by a single
reaction – normal pattern corresponding to the homozygous
wild type. Colour is assigned to individual ddNTPs as follows:
green/A, black/C, blue/G, red/T.
Figure 6
Analysis of the three nucleotides of codon 634 by a multiplex
reaction – pattern observed in an individual heterozygous for
the mutation G/A at the second position. Colour is assigned
to individual ddNTPs as follows: green/A, black/C, blue/G,
red/T.Page 3 of 5
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DNA extraction
High molecular weight DNA from white blood cells was
prepared using the guanidine-HCl method adapted from
Sambrook [18].
DNA amplification and purification
Seven DNA samples from different individuals represent-
ative of 5 MEN 2A families, 1 FMTC family and a de novo
case of MEN 2B were assayed. All were known to harbour
a germline mutation in the RET proto oncogene. Four car-
ried a C634R mutation, two a C634Y mutation and one a
M918T mutation. Adequate negative controls were in-
cluded.
Approximately 100 ng of genomic DNA was amplified in
a 40 µl reaction containing 20 mM Tris-HCl (pH 8.4), 50
mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 2 units of Taq
polymerase and 1 µM of each primer. To amplify exon 11
(codon 634) the primers used were CRT19A and CRT19B
[7]; to amplify exon 16 (codon 918) the primers used
were 16F and 16 R [6]. Genomic DNA was denatured for
5 minutes at 94°C prior to 35 cycles of denaturation for 45
seconds at 94°C, annealing for 45 seconds at 62°C and ex-
tension for 45 seconds at 72°C followed by a 7 minute
72°C polishing step. The reactions were run on a UNO II
thermocycler (Biometra, Göttingen, Germany).
PCR products were purified through low melting point
agarose and eluted using the Wizard PCR Preps kit
(Promega, Southampton, Hants, UK) according to the
manufacturer's protocol.
The minisequencing method
We adapted the ABI PRISM SNaPshot™ ddNTP Primer Ex-
tension Kit (Applied Biosystems, USA) to mutational
analysis of MEN 2 families. This technique was primarily
devised to detect single nucleotide polymorphisms
(SNPs). It depends on a primer extension reaction starting
from the purified amplified target. A specific minise-
quencing primer, which is exactly one base short of the
polymorphic site, is used for each nucleotide to be stud-
ied. Primer extension reactions are carried out using fluo-
rescent labelled dideoxynucleotides (F ddNTP).
Incorporation of the labelled nucleotide is dependent on
the genotype. Interruption of the reaction occurs after in-
corporation of only one terminator. Since purification
steps are not necessary, the product obtained is immedi-
ately separated electrophoretically; the colour of the peaks
obtained makes it possible to identify the SNP or muta-
tion.
In order to search for 634 mutations two different ap-
proaches were used. First we interrogated each nucleotide
separately, performing 3 reactions and using only one
primer in each reaction. Thereafter the three nucleotides
were interrogated simultaneously performing a multiplex
reaction with three primers. Both single and multiplex re-
actions were performed according to the manufacturer's
instructions. Primers were designed to interrogate the
three nucleotides and as so to identify any mutation at
this codon: 11SST-T 5' atc cac tgt gcg acg agc tg 3'; 11SST-
G 5' ccc cca tcc act gtg cga cga gct gt 3'; 11SST-C 5' aaa aaa
aaa aat cca ctg tgc gac gag ctg tg 3'.
The M918T mutation was easily detected using a specific
primer, 16SST-T 5' tcg gat tcc agt taa atg ga 3', one base
Figure 7
Analysis of the second nucleotide of codon 918 by a single
reaction – pattern observed in an individual heterozygous for
the mutation T/C at the second position. Colour is assigned
to individual ddNTPs as follows: green/A, black/C, blue/G,
red/T.
Figure 8
Analysis of the second nucleotide of codon 918 by a single
reaction – normal pattern corresponding to the homozygous
wild type. Colour is assigned to individual ddNTPs as follows:
green/A, black/C, blue/G, red/T.Page 4 of 5
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action.
The separation of the products obtained was performed
using the ABI PRISM® 310 Genetic Analyzer (Applied Bio-
systems, USA) with POP 4 polymer, 47 cm capillary. Run
time approximately 12 minutes. The peak signal was ana-
lysed with the GeneScan Analysis Software version 3.1.
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